+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adalimumab Drugs Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 140 Pages
  • February 2024
  • Region: Global
  • Expert Market Research
  • ID: 5941041

Global Adalimumab Drugs Market Outlook

The global adalimumab drugs market size is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032, driven by entry of biosimilar versions of adalimumab into the market across the globe.

Adalimumab: Introduction

Adalimumab is a biologic medication used to treat a variety of autoimmune diseases by targeting and inhibiting tumor necrosis factor (TNF), a substance in the body that causes inflammation. It is commonly used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Administered via injection, adalimumab helps reduce inflammation, relieve symptoms, and prevent disease progression. It is a crucial option for patients who have not responded to traditional treatments.

Key Trends in the Global Adalimumab Drugs Market

The entry of biosimilar versions of adalimumab into the market is a significant trend, especially as the patent for the original brand-name drug, Humira, has expired in many regions. This has led to increased competition, offering more affordable treatment options for patients and influencing pricing and market dynamics across regions.

Continuous research and clinical trials have expanded adalimumab's approved indications to include a broader range of autoimmune diseases. This expansion has driven its usage in new patient populations, contributing to the growth of its market presence.

There's a growing trend towards personalized medicine in the adalimumab drugs market, with efforts to identify biomarkers that predict patient response to the medication. This approach aims to optimize treatment outcomes and reduce unnecessary exposure to the drug for non-responders, enhancing overall patient care.

Pharmaceutical companies are engaging in strategic collaborations and partnerships to enhance the development and distribution of adalimumab biosimilars. These collaborations aim to leverage manufacturing capabilities, regulatory expertise, and market access, facilitating the global availability of biosimilars.

Manufacturers of adalimumab and its biosimilars are increasingly focusing on patient support programs to improve treatment adherence and patient outcomes. These programs offer financial assistance, educational resources, and injection training, which are critical for maintaining long-term therapy with injectable biologics.

The regulatory landscape for biosimilars is evolving, with agencies in North America, Europe, and other regions establishing clearer pathways for biosimilar approval. This trend is crucial for ensuring the safety, efficacy, and interchangeability of biosimilars with their reference products, influencing market acceptance and growth.

Global Adalimumab Drugs Market Segmentation

Market Breakup by Indication

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Chronic Plaque Psoriasis
  • Crohn's Disease
  • Ulcerative Colitis
  • Others

Market Breakup by Type

  • Biologics
  • Biosimilars

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by Age Group

  • Pediatric
  • Adult
  • Geriatric

Market Breakup by Distribution Channel

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Adalimumab Drugs Market Overview

In North America, the adalimumab market is mature, with a strong emphasis on treating autoimmune diseases. The region has witnessed a significant adoption of biosimilars following the expiration of patent protections, increasing competition and accessibility. There's a focus on personalized medicine to tailor treatments to individual patient needs, supported by advanced healthcare infrastructure and comprehensive insurance coverage.

Europe's market has seen a rapid increase in the adoption of adalimumab biosimilars, driven by supportive regulatory frameworks and policies promoting biosimilar use to reduce healthcare costs. The region prioritizes access to biologic therapies for patients with autoimmune diseases, with healthcare systems in various countries actively negotiating prices to enhance affordability.

The Asia-Pacific adalimumab market is growing, driven by increasing awareness of autoimmune diseases, improving healthcare infrastructure, and rising healthcare spending. The demand for biologic therapies is expanding, particularly in countries like China and India, though accessibility varies across the region. Efforts to introduce biosimilars and make treatments more affordable are key trends.

Global Adalimumab Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc. (US)
  • Biogen
  • Fresenius Kabi AG
  • Zydus Cadila
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • AbbVie Inc.
  • Abbott
  • CELLTRION INC.
  • Samsung Bioepis


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Adalimumab Drugs Market Overview
3.1 Global Adalimumab Drugs Market Historical Value (2017-2023)
3.2 Global Adalimumab Drugs Market Forecast Value (2024-2032)
4 Global Adalimumab Drugs Market Landscape
4.1 Global Adalimumab Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Adalimumab Drugs Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
4.2.3 Analysis by Route of Administration
5 Global Adalimumab Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Adalimumab Drugs Market Segmentation
6.1 Global Adalimumab Drugs Market by Indication
6.1.1 Market Overview
6.1.2 Rheumatoid Arthritis
6.1.3 Psoriatic Arthritis
6.1.4 Ankylosing Spondylitis
6.1.5 Chronic Plaque Psoriasis
6.1.6 Crohn's Disease
6.1.7 Ulcerative Colitis
6.1.8 Others
6.2 Global Adalimumab Drugs Market by Type
6.2.1 Market Overview
6.2.2 Biologics
6.2.3 Biosimilars
6.3 Global Adalimumab Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Others
6.4 Global Adalimumab Drugs Market by Age Group
6.4.1 Market Overview
6.4.2 Pediatric
6.4.3 Adult
6.4.4 Geriatric
6.5 Global Adalimumab Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Specialty Clinics
6.5.4 Homecare
6.5.5 Others
6.6 Global Adalimumab Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Adalimumab Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Adalimumab Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Adalimumab Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Adalimumab Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Adalimumab Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 F. Hoffmann-La Roche Ltd.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Mylan N.V.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Teva Pharmaceutical Industries Ltd.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sanofi
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 GlaxoSmithKline plc
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Novartis AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Pfizer Inc. (US)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Biogen
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Fresenius Kabi AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Zydus Cadila
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Boehringer Ingelheim International GmbH
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Amgen Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 AbbVie Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Abbott
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 CELLTRION INC.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Samsung Bioepis
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
18 Global Adalimumab Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • F. Hoffmann-La Roche Ltd. Mylan N.V. Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • GlaxoSmithKline plc Novartis AG Pfizer Inc. (US)
  • Biogen
  • Fresenius Kabi AG
  • Zydus Cadila
  • Boehringer Ingelheim International GmbH
  • Amgen Inc. AbbVie Inc.
  • Abbott
  • CELLTRION INC.
  • Samsung Bioepis

Methodology

Loading
LOADING...